Holen Sie sich die Stockscreener-App
12.29
4.86%
0.57
Handel nachbörslich:
12.50
0.21
+1.71%
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
What’s next for Atara Biotherapeutics Inc. stock priceJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
Understanding Atara Biotherapeutics Inc.’s price movementChart Signals & AI Enhanced Trading Signals - Newser
Measuring Atara Biotherapeutics Inc.’s beta against major indicesJuly 2025 Drop Watch & Accurate Intraday Trading Signals - Newser
Atara Biotherapeutics Inc. Rebound Backed by Sentiment ShiftPortfolio Performance Summary & Short-Term High Return Strategies - newsyoung.net
Risk vs reward if holding onto Atara Biotherapeutics Inc.2025 Trading Volume Trends & Weekly High Return Stock Opportunities - Newser
Elliott Wave Theory Predicts Pullback in Atara Biotherapeutics Inc.Portfolio Gains Report & Low Risk High Reward Trade Ideas - sundaytimes.kr
How high can Atara Biotherapeutics Inc. stock goTrade Risk Assessment & High Win Rate Trade Alerts - Newser
Atara Biotherapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Why Atara Biotherapeutics Inc. is moving todayQuarterly Trade Report & Proven Capital Preservation Methods - Newser
Multi asset correlation models including Atara Biotherapeutics Inc.2025 Market Sentiment & Reliable Price Action Trade Plans - Newser
Atara Biotherapeutics Inc. stock daily chart insightsMarket Volume Report & Low Drawdown Momentum Trade Ideas - Newser
How to interpret RSI for Atara Biotherapeutics Inc. stockQuarterly Investment Review & Safe Entry Momentum Tips - Newser
What does recent volatility data suggest for Atara Biotherapeutics Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
Using Python tools to backtest Atara Biotherapeutics Inc. strategiesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise - simplywall.st
Will Atara Biotherapeutics Inc. bounce back from current supportIPO Watch & Accurate Technical Buy Alerts - Newser
Risk adjusted return profile for Atara Biotherapeutics Inc. analyzedFree Early Entry Picks Before News Breakout - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyStrong ROI Equity Ideas - kangso.co.kr
Is Atara Biotherapeutics Inc. building a consolidation baseDaily Investment Ideas with Market Insight - Newser
Atara Biotherapeutics: Q2 Earnings Snapshot - Norwalk Hour
Technical signs of recovery in Atara Biotherapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
How Atara Biotherapeutics Inc. stock performs during market volatilityConsistent Gain Plan with AI Support - Newser
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics shares rise 2.13% after-hours after FDA accepted BLA for tabelecleucel. - AInvest
Atara Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Q2 Financial Results, Resumes Strategic Options Evaluation - AInvest
Will Atara Biotherapeutics Inc. price bounce be sustainableCapital Safe Picks with Consistent Gains - Newser
What MACD signals say about Atara Biotherapeutics Inc.High Return Idea With Technical Filter - Newser
Is Atara Biotherapeutics Inc. showing signs of accumulationBuy Strategy Tracker with Growth Indicators - Newser
Atara Biotherapeutics (ATRA) Projected to Post Quarterly Earnings on Monday - Defense World
Atara ATRA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Atara Biotherapeutics Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Biotech with Heart: Atara’s Path to Hope for MS & Cancer - Tomorrow's World Today
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - sg.finance.yahoo.com
What is Atara Biotherapeutics Inc. company’s growth strategyUnlock powerful portfolio management tools - Jammu Links News
Is Atara Biotherapeutics Inc. stock ready for a breakoutHigh Return Trade Roadmap with Setup Filters - Newser
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsStrong return on investment - Jammu Links News
What are the latest earnings results for Atara Biotherapeutics Inc.Rapid wealth multiplication - Jammu Links News
Does Atara Biotherapeutics Inc. stock perform well during market downturnsHigh-yield trading alerts - Jammu Links News
When is Atara Biotherapeutics Inc. stock expected to show significant growthUnlock powerful portfolio optimization tools - Jammu Links News
What analysts say about Atara Biotherapeutics Inc. stockDiscover stocks with explosive upside potential - Jammu Links News
Should I hold or sell Atara Biotherapeutics Inc. stock in 2025Maximize profits with strategic stock selection - Jammu Links News
What institutional investors are buying Atara Biotherapeutics Inc. stockTriple-digit wealth increases - Jammu Links News
What are Atara Biotherapeutics Inc. company’s key revenue driversGet real-time alerts on top-performing stocks - Jammu Links News
What drives Atara Biotherapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the dividend policy of Atara Biotherapeutics Inc. stockMaximize returns with disciplined trading approaches - Jammu Links News
What catalysts could drive Atara Biotherapeutics Inc. stock higher in 2025Discover high-growth stocks for your portfolio - Jammu Links News
Why is Atara Biotherapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed trading alerts - Jammu Links News
Is it the right time to buy Atara Biotherapeutics Inc. stockConsistent high-yield stocks - Jammu Links News
FDA Accepts Atara Biotherapeutics’ Resubmission of BLA for Tabelecleucel - CGTLive®
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):